Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately

Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, Incorporated for allegedly making false and misleading statements regarding the New Drug Application (NDA) for aficamten, which could impact the company's regulatory approval timeline [1][8]. Allegations - Defendants are accused of making materially false statements about the expected timeline for the NDA submission and approval process for aficamten, claiming FDA approval was anticipated in the second half of 2025 with a PDUFA date of September 26, 2025 [8]. - The company allegedly failed to disclose significant risks, particularly the omission of a required Risk Evaluation and Mitigation Strategy (REMS), which could lead to delays in regulatory approval [8]. Key Dates - Investors must contact the law firm before November 17, 2025, to be eligible for the lead plaintiff motion deadline [4]. Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP, with over 125 years of experience in securities litigation, is representing the investors in this case, emphasizing their commitment to justice for those financially harmed by misrepresented statements [5].